Tuesday, March 8, 2016

Tizona Therapeutics Finds $43M In Series B

South San Francisco-based Tizona Therapeutics said this morning that it has raised $43M in a Series B funding round. The funding came from Abingworth and Canaan Partners along with Lightstone Ventures, MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners. The company says it has now raised a total of more than $70M. Shelly Chu of Abingworth, Nina Kjellson of Canaan, and Jean George of Lightstone Ventures all join the board with the funding. Tizona is developing treatments for cancer and autoimmune diseases. More information »